相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status
Gail J. Roboz et al.
BLOOD (2022)
Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
Juliane Grimm et al.
BLOOD CANCER JOURNAL (2022)
The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies
Victoria C. Brom et al.
FRONTIERS IN IMMUNOLOGY (2022)
DNA hypomethylating agents increase activation and cytolytic activity of CD8+T cells
Helen Loo Yau et al.
MOLECULAR CELL (2021)
Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
Xiang-Mei Wen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy
Hussein A. Abbas et al.
BLOOD ADVANCES (2021)
M3C: Monte Carlo reference-based consensus clustering
Christopher R. John et al.
SCIENTIFIC REPORTS (2020)
Immune escape and immunotherapy of acute myeloid leukemia
Luca Vago et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Expression patterns of immune checkpoints in acute myeloid leukemia
Cunte Chen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
David A. Sallman et al.
BLOOD (2020)
Acute myeloid leukemia: 2021 update on risk-stratification and management
Elihu H. Estey
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia
Therese Vu et al.
NATURE COMMUNICATIONS (2020)
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
A. H. Wei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
Peter van Galen et al.
CELL (2019)
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia
Bruno C. Medeiros et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations
Barbora Brodska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Patrick Williams et al.
CANCER (2019)
Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance
Jing-Ni Sui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion
Lyndsay Avery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity
Adam J. Lamble et al.
FRONTIERS IN ONCOLOGY (2018)
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy
Hanna A. Knaus et al.
JCI INSIGHT (2018)
Dissecting the Immune Landscape of Acute Myeloid Leukemia
Jan Davidson-Moncada et al.
BIOMEDICINES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation
Florian Wolff et al.
CELL COMMUNICATION AND SIGNALING (2017)
Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion
Eunseon Ahn et al.
JOURNAL OF VIROLOGY (2016)
Acute Myeloid Leukemia: A Concise Review
Jennifer N. Saultz et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
Y. Kong et al.
BLOOD CANCER JOURNAL (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
Eric Laille et al.
PLOS ONE (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Julie R. Brahmer et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia
Xiangli Chen et al.
CANCER BIOLOGY & THERAPY (2008)
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Carlo Stresemann et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Azacytidine causes complex DNA methylation responses in myeloid leukemia
Carlo Stresemann et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
